Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Liabilities and Shareholders Equity (2016 - 2025)

Marimed has reported Liabilities and Shareholders Equity over the past 15 years, most recently at $202.6 million for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 2.14% to $202.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $820.5 million through Dec 2025, down 1.08% year-over-year, with the annual reading at $202.6 million for FY2025, 2.14% down from the prior year.
  • Liabilities and Shareholders Equity was $202.6 million for Q4 2025 at Marimed, down from $205.6 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $212.7 million in Q3 2024 and troughed at $90.0 million in Q1 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $190.1 million (2023), against an average of $170.7 million.
  • Year-over-year, Liabilities and Shareholders Equity skyrocketed 63.2% in 2021 and then decreased 3.33% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $123.2 million in 2021, then grew by 23.54% to $152.2 million in 2022, then increased by 28.86% to $196.1 million in 2023, then grew by 5.54% to $207.0 million in 2024, then decreased by 2.14% to $202.6 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Liabilities and Shareholders Equity are $202.6 million (Q4 2025), $205.6 million (Q3 2025), and $204.4 million (Q2 2025).